Torrent Pharmaceuticals Share Price, Fundamentals and Financials
Track live share price, 52 week range, chart views, fundamentals, business segments, financial highlights, ratios, peers, corporate actions and FAQs.
₹4,660.90
+₹3.30 · +0.07%
Torrent Pharmaceuticals price chart
Switch between 1 Day, 5 Day, 1 Month and 1 Year views.
Chart data is temporarily unavailable.
Quick Fundamentals
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited is an Ahmedabad-headquartered pharmaceutical company that develops, manufactures and markets branded and generic formulations in India and international markets.
Its important therapy areas include cardiovascular, central nervous system, gastro-intestinal, diabetology, women’s healthcare and dermatology. Investors typically monitor India prescription growth, Brazil, Germany, the United States, margins, launches, regulation, acquisitions, debt and cash generation.
Business Model and Segments
The company sells pharmaceutical formulations through distributors, pharmacies, hospitals and institutional channels. India is a major branded-formulations market, while international operations include branded generics and generics in Brazil, Germany, the United States and other markets.
Performance depends on product mix, pricing, manufacturing utilisation, research spending, approvals, sales-force productivity, currency movements and competition. Customers should use medicines only under appropriate medical guidance.
Profit and Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Revenue from Operations | ₹9,620 Cr | ₹10,728 Cr | ₹11,516 Cr |
| Operating Profit | ₹2,694 Cr | ₹3,328 Cr | ₹3,726 Cr |
| Operating Margin | 28.0% | 31.0% | 32.4% |
| Profit Before Tax | ₹1,939 Cr | ₹2,585 Cr | ₹3,091 Cr |
| Net Profit | ₹1,245 Cr | ₹1,656 Cr | ₹1,911 Cr |
| EPS | ₹36.78 | ₹48.92 | ₹56.45 |
Educational snapshot; verify the latest audited figures and restatements from official filings.
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Equity Capital | ₹169 Cr | ₹169 Cr | ₹169 Cr |
| Reserves | ₹7,320 Cr | ₹8,357 Cr | ₹9,595 Cr |
| Borrowings | ₹5,154 Cr | ₹4,405 Cr | ₹3,873 Cr |
| Other Liabilities | ₹3,289 Cr | ₹3,643 Cr | ₹4,184 Cr |
| Total Assets | ₹15,932 Cr | ₹16,574 Cr | ₹17,821 Cr |
Verify the latest audited balance sheet from official filings.
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Operating Cash Flow | ₹1,968 Cr | ₹2,716 Cr | ₹2,755 Cr |
| Investing Cash Flow | -₹474 Cr | -₹663 Cr | -₹738 Cr |
| Financing Cash Flow | -₹1,514 Cr | -₹1,923 Cr | -₹1,863 Cr |
| Net Cash Flow | -₹20 Cr | ₹130 Cr | ₹154 Cr |
Verify current cash-flow figures from official filings.
Key Ratios
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Operating Margin | 28.0% | 31.0% | 32.4% |
| Return on Equity | Approx. 18% | Approx. 21% | Approx. 21% |
| Debt to Equity | Approx. 0.69x | Approx. 0.52x | Approx. 0.40x |
| Interest Coverage | Approx. 6.7x | Approx. 8.2x | Approx. 10.4x |
Ratio definitions vary by data provider; verify methodology and the latest period.
Peer Comparison
| Company | NSE Symbol | Business Focus | Key Comparison Points |
|---|---|---|---|
| Torrent Pharmaceuticals | TORNTPHARM | Branded generics and formulations | India chronic therapies, international markets, margins and debt |
| Sun Pharma | SUNPHARMA | Specialty and generics | Scale, specialty pipeline and global exposure |
| Cipla | CIPLA | Respiratory and generics | India growth, US pipeline and margins |
| Dr. Reddy’s | DRREDDY | Global generics and APIs | US launches, emerging markets and regulation |
| Lupin | LUPIN | Generics and specialty | US recovery, India growth and margins |
Use comparable reporting periods and current market data when comparing peers.
Dividends and Bonuses / Splits
| Year | Dividend Detail | Note |
|---|---|---|
| Latest declaration | Verify amount and type | Check NSE, BSE and company filings |
| Historical record | Dividends paid in the past | Past payouts do not guarantee future payouts |
| Action | Detail | Note |
|---|---|---|
| Bonus Issue | 1:1 bonus in 2022 | Verify ex-date and record date |
| Earlier Bonuses | Reported in 2013 and 2006 | Confirm adjusted history |
| Stock Split | No recent split highlighted | Check official corporate-action history |
Verify the latest dividend, bonus, split, face value, record date and ex-date from official exchange filings.
Torrent Pharmaceuticals customer and investor FAQs
What does Torrent Pharmaceuticals do?
Torrent Pharmaceuticals develops, manufactures and markets branded and generic pharmaceutical formulations. Its portfolio includes cardiovascular, central nervous system, gastro-intestinal, diabetology, women’s healthcare, dermatology and selected acute therapies.
What is the NSE and BSE code of Torrent Pharmaceuticals?
The NSE symbol is TORNTPHARM, the BSE scrip code is 500420, and the Yahoo Finance-compatible NSE symbol used here is TORNTPHARM.NS.
How does Torrent Pharmaceuticals make money?
The company earns revenue from prescription medicines and formulations sold in India and international markets. Results depend on volumes, pricing, launches, product mix, manufacturing efficiency, regulation and currency movements.
Which markets are important for Torrent Pharmaceuticals?
India is a major market. International operations include Brazil, Germany, the United States and other regulated or emerging markets. Each geography has different pricing, competition and regulatory conditions.
What should beginners monitor?
Monitor revenue, operating margin, profit, debt, cash flow, India prescription growth, international performance, launches, regulatory inspections, acquisitions and management guidance.
What are the main risks?
Risks include regulatory observations, approval delays, generic price erosion, competition, litigation, recalls, raw-material costs, currency volatility, acquisition integration and debt.
Does Torrent Pharmaceuticals pay dividends?
The company has paid dividends in the past. Verify the latest amount, ex-date, record date and payment date from official NSE, BSE or company filings.
Has Torrent Pharmaceuticals issued bonus shares or splits?
The company issued a 1:1 bonus in 2022 and earlier bonus issues are also reported. Verify all corporate actions from official exchange filings.
How can investors track shareholding?
Review quarterly shareholding filings for promoter, FII, DII and public ownership on NSE, BSE or the company investor-relations website.
What can affect the share price?
Quarterly results, margins, launches, regulatory news, acquisitions, litigation, dividends, pharma-sector sentiment, currency movements and broader markets can affect the price.
How should peers be compared?
Compare revenue mix, India growth, international exposure, margins, returns, debt, research spending, regulatory history, valuation and cash generation using the same reporting period.
Where can customers find product information?
Use the official company website, medicine packaging and advice from a qualified healthcare professional. This page is not medical advice.
Is the share suitable for investment?
Suitability depends on goals, risk capacity and time horizon. This page does not provide a buy or sell recommendation.